3DBioFibR Inc., a leading manufacturer of advanced biopolymer fibers, today announced the successful close of a $3 million equity financing round. The raise follows a string of recently signed paid partnerships and collaborations across key sectors including tissue engineering, medical devices, defense, cosmetics, and apparel with several multinational corporations.
Strong Investor Support Fuels Growth
The funding round drew participation from both new and existing investors, including AoA Innovation Fund, Build Ventures, Invest Nova Scotia, and Concrete Ventures. This financing represents an important milestone for 3DBioFibR as it improves operational scale and deepens its role as a critical supplier of next-generation biomaterials.
Kevin Sullivan, CEO of 3DBioFibR, commented on the significance of this investment:
This investment fuels the next phase of our growth. It enables us to meet growing demand from our commercial partners and to become a qualified supplier for regulated medical and therapeutic applications. ISO 13485 certification is a key step in delivering clinical-grade fibers at the scale and consistency our partners require. We're excited to expand our impact across industries that urgently need stronger, more sustainable biomaterials.
Strategic Investment in Manufacturing Excellence
The raised capital will support increased manufacturing capacity to meet growing commercial demand while enabling operational growth across the organization. A key focus of the funding will be implementing ISO 13485 certification, including the construction of a clean room manufacturing facility essential for producing medical-grade materials. This certification represents a critical step in 3DBioFibR's evolution from innovative startup to qualified supplier for regulated medical and therapeutic applications.
Proven Commercial Traction Across Industries
Over the past two years, 3DBioFibR has secured paid development agreements with a growing roster of global and regional companies developing products in tissue engineering, medical devices, defense, cosmetics, and apparel. These partnerships focus on integrating 3DBioFibR's best-in-class fibers into existing and developing product pipelines. The new capital ensures the company can continue to deliver high-performance materials at commercial scale, while laying the groundwork for expanded clinical partnerships.
Patrick Keefe, General Partner at Build Ventures, praised the company's achievements:
3DBioFibR has accomplished something rare, translating cutting-edge biomaterials science into real commercial traction. They've partnered with serious players in global industries and built a manufacturing platform that can deliver fibers at a scale and quality the market hasn't seen before. This team is setting the benchmark in biopolymer fiber manufacturing, and we're proud to support their journey.
Proprietary Manufacturing Technology
3DBioFibR's proprietary dry-spinning platform enables the production of fibers from a wide range of biopolymers, currently over six different types, with performance metrics that meet or exceed natural tissue strength by two to three times. Compared to conventional techniques like wet spinning and electrospinning, 3DBioFibR's process delivers material at over 3,600 times the scale, with vastly improved uniformity and cost-efficiency.
These remarkable properties position the company's fibers for use in applications where strength, biocompatibility, or scale have previously been limiting factors. The technology's versatility allows 3DBioFibR to work with multiple biopolymer types, from collagen to spider silk, opening doors to transformative applications across diverse industries.
Long-term Vision Backed by Strategic Investors
Lidija Marušić from Invest Nova Scotia highlighted the company's unique position in the market:
As an early investor in 3DBioFibR, Invest Nova Scotia has been active with the company throughout its growth into a unique business that offers novel and unparalleled manufacturing potential for biopolymer applications, representing multibillion-dollar market opportunities. With this latest investment, Invest Nova Scotia looks forward to seeing 3DBioFibR achieve their objectives.
The investor confidence reflects the significant market opportunity that 3DBioFibR is positioned to capture as industries increasingly seek sustainable, high-performance alternatives to traditional materials.
About 3DBioFibR
3DBioFibR is driving the adoption of biomaterials in regenerative medicine, medical devices, defense, cosmetics, and sustainable textiles. Its patented dry-spinning technology enables scalable, high-precision manufacturing of advanced biopolymer fibers, delivering superior performance at industrial scales. By collaborating with industry leaders, 3DBioFibR is unlocking transformative applications for strong, lightweight, and biocompatible materials across some of the world's most demanding sectors.
Powering Growth with Scispot's Digital Infrastructure
As 3DBioFibR scales its operations and works toward ISO certification, the company has partnered with Scispot to streamline its laboratory operations and data management. The transition from paper-based systems to Scispot's digital platform has been instrumental in centralizing experiments, improving inventory management, and preparing for regulatory compliance.
Dana Bhattacharyya, Director of Operations at 3DBioFibR, explains: "Scispot has been instrumental in centralizing our experiments and inventory management in one place, which has significantly improved our workflow efficiency. We're now moving towards an ISO 9001 certification, and having a platform that is 21 CFR Part 11 compliant is invaluable for this process."
This digital transformation has enabled 3DBioFibR to build the quality systems and documentation standards necessary for scaling their innovative biopolymer manufacturing platform while maintaining the rigor required for regulated applications.
For more information about 3DBioFibR, visit www.3dbiofibr.com
